Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.82)
# 3,901
Out of 4,974 analysts
32
Total ratings
28%
Success rate
-14.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $9.90 | +203.18% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $37.88 | +58.39% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $11.65 | +114.59% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $10.52 | +185.17% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $20.29 | +62.64% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $3.54 | +125.99% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $27.16 | +84.09% | 2 | Feb 14, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.15 | +109.79% | 2 | Jan 22, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $43.50 | +37.93% | 2 | Jan 21, 2025 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.58 | +216.46% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $2.72 | +47.06% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.83 | +602.43% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.91 | +580.63% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.32 | +1,101.92% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.79 | +616.85% | 1 | May 14, 2024 |
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $9.90
Upside: +203.18%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $37.88
Upside: +58.39%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $11.65
Upside: +114.59%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $10.52
Upside: +185.17%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $20.29
Upside: +62.64%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.54
Upside: +125.99%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $27.16
Upside: +84.09%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.15
Upside: +109.79%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $43.50
Upside: +37.93%
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.58
Upside: +216.46%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $2.72
Upside: +47.06%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.83
Upside: +602.43%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.91
Upside: +580.63%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.32
Upside: +1,101.92%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.79
Upside: +616.85%